Published • loading... • Updated
Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C
Summary by News Medical
1 Articles
1 Articles
Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C
In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
